Citations

Clear

813 citation(s) found for "He, Helen".

Trial Readiness of Cavernous Malformations With Symptomatic Hemorrhage, Part II: Biomarkers and Trial Modeling
Hage, Stephanie , Kinkade, Serena , Flemming, Kelly D. , Kim, Helen , Torbey, Michel , Huang, Judy , Huston, John , Shu, Yunhong , Selwyn, Reed , Hart, Blaine L. , Feghali, James , Sair, Haris I. , Narvid, Jared , Lupo, Janine , Stadnik, Agnieszka , Hobson, Nicholas , DeBiasse, Dorothy , Lane, Karen , McBee, Nichole, Treine, Kevin, Ostapkovich, Noeleen , Wang, Ying, Thompson, Richard E. , Awad, Issam A. , Huston, John , Flemming, Kelly D , Kim, Helen , Torbey, Michel , Huang, Judy , Shu, Yunhong , Selwyn, Reed , Feghali, James , Narvid, Jared , Alcazar-Felix, Roberto J , Shenkar, Robert , Hobson, Nicholas , DeBiasse, Dorothy , Lane, Karen , Ostapkovich, Noeleen , Koenig, James I , Carroll, Timothy , Hanley, Daniel F , Awad, Issam , Girard, Romuald , Mabray, Marc C. , Lee, Justine C. , Alcazar‐Félix, Roberto J. , Shenkar, Robert , Koenig, James I. , Hanley, Daniel F.

Mayo Clinic

Stroke | December 22, 2023 | Volume: 55 | Issue: 1 | Pages: 31-39

10.1161/strokeaha.123.044083 | PMID 38134265 Get It

BACKGROUND: Quantitative susceptibility mapping (QSM) and dynamic contrast-enhanced quantitative perfusion (DCEQP) magnetic resonance imaging sequences assessing iron deposition and vascular permeability were previously correlated with new hemorrhage in cerebral cavernous malformations. We assessed their prospective changes in a multisite trial-readiness project. METHODS: Patients with cavernous malformation and symptomatic hemorrhage (SH) in the prior year, without prior or planned lesion resection or irradiation were enrolled. Mean QSM and DCEQP of the SH lesion were acquired at baseline and at 1- and 2-year follow-ups. Sensitivity and specificity of biomarker changes were analyzed in relation to predefined criteria for recurrent SH or asymptomatic change. Sample size calculations for hypothesized therapeutic effects were conducted. RESULTS: We logged 143 QSM and 130 DCEQP paired annual assessments. Annual QSM change was greater in cases with SH than in cases without SH ( P =0.019). Annual QSM increase by ≥6% occurred in 7 of 7 cases (100%) with recurrent SH and in 7 of 10 cases (70%) with asymptomatic change during the same epoch and 3.82× more frequently than clinical events. DCEQP change had lower sensitivity for SH and asymptomatic change than QSM change and greater variance. A trial with the smallest sample size would detect a 30% difference in QSM annual change during 2 years of follow-up in 34 or 42 subjects (1 and 2 tailed, respectively); power, 0.8, α=0.05. CONCLUSIONS: Assessment of QSM change is feasible and sensitive to recurrent bleeding in cavernous malformations. Evaluation of an intervention on QSM percent change may be used as a time-averaged difference between 2 arms using a repeated measures analysis. DCEQP change is associated with lesser sensitivity and higher variability than QSM. These results are the basis of an application for certification by the US Food and Drug Administration of QSM as a biomarker of drug effect on bleeding in cavernous malformations. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03652181.
Trial Readiness of Cavernous Malformations With Symptomatic Hemorrhage, Part I: Event Rates and Clinical Outcome
Flemming, Kelly D. , Kim, Helen , Hage, Stephanie , Mandrekar, Jay , Kinkade, Serena , Torbey, Michel , Huang, Judy , Huston, John , Shu, Yunhong , Selwyn, Reed , Hart, Blaine L. , Feghali, James , Sair, Haris I. , Narvid, Jared , Lupo, Janine , Stadnik, Agnieszka , Lane, Karen , McBee, Nichole, Treine, Kevin, Ostapkovich, Noeleen , Wang, Ying , Thompson, Richard E. , Awad, Issam A. , Huston, John , Torbey, Michel , Huang, Judy , Shu, Yunhong , Lanzino, Giuseppe , Selwyn, Reed , Hart, Blaine , Mabray, Marc C , Feghali, James , Narvid, Jared , Alcazar-Felix, Roberto J , Shenkar, Robert , Lane, Karen , Ostapkovich, Noeleen , Koenig, James I , Carroll, Timothy , Hanley, Daniel F , Awad, Issam , Flemming, Kelly D , Kim, Helen , Girard, Romuald , Lanzino, Giuseppe , Mabray, Marc C. , Lee, Justine C. , Alcazar‐Félix, Roberto J. , Shenkar, Robert , Koenig, James I. , Hanley, Daniel F.

Mayo Clinic

Stroke | December 22, 2023 | Volume: 55 | Issue: 1 | Pages: 22-30

10.1161/strokeaha.123.044068 | PMID 38134268 Get It

BACKGROUND: Cerebral cavernous malformation with symptomatic hemorrhage (SH) are targets for novel therapies. A multisite trial-readiness project ( https://www.clinicaltrials.gov ; Unique identifier: NCT03652181) aimed to identify clinical, imaging, and functional changes in these patients. METHODS: We enrolled adult cerebral cavernous malformation patients from 5 high-volume centers with SH within the prior year and no planned surgery. In addition to clinical and imaging review, we assessed baseline, 1- and 2-year National Institutes of Health Stroke Scale, modified Rankin Scale, European Quality of Life 5D-3 L, and patient-reported outcome-measurement information system, Version 2.0. SH and asymptomatic change rates were adjudicated. Changes in functional scores were assessed as a marker for hemorrhage. RESULTS: One hundred twenty-three, 102, and 69 patients completed baseline, 1- and 2-year clinical assessments, respectively. There were 21 SH during 178.3 patient years of follow-up (11.8% per patient year). At baseline, 62.6% and 95.1% of patients had a modified Rankin Scale score of 1 and National Institutes of Health Stroke Scale score of 0 to 4, respectively, which improved to 75.4% ( P =0.03) and 100% ( P =0.06) at 2 years. At baseline, 74.8% had at least one abnormal patient-reported outcome-measurement information system, Version 2.0 domain compared with 61.2% at 2 years ( P =0.004). The most common abnormal European Quality of Life 5D-3 L domains were pain (48.7%), anxiety (41.5%), and participation in usual activities (41.4%). Patients with prospective SH were more likely than those without SH to display functional decline in sleep, fatigue, and social function patient-reported outcome-measurement information system, Version 2.0 domains at 2 years. Other score changes did not differ significantly between groups at 2 years. The sensitivity of scores as an SH marker remained poor at the time interval assessed. CONCLUSIONS: We report SH rate, functional, and patient-reported outcomes in trial-eligible cerebral cavernous malformation with SH patients. Functional outcomes and patient-reported outcomes generally improved over 2 years. No score change was highly sensitive or specific for SH and could not be used as a primary end point in a trial.
NRG‐GY012: Randomized phase 2 study comparing olaparib, cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent, or metastatic endometrial cancer
Rimel, B.J. , Enserro, Danielle , Bender, David , Jackson, Camille Gunderson, Tan, Annie , Alluri, Nitya , Borowsky, Mark E., Moroney, John W. , Hendrickson, Andrea Wahner, Backes, Floor , Swisher, Elizabeth M. , Powell, Matthew A. , Mackay, Helen , Rimel, Bobbie J , Swisher, Elizabeth M , Backes, Floor

Mayo Clinic

Cancer | December 21, 2023 | Volume: 130 | Issue: 8 | Pages: 1234-1245

10.1002/cncr.35151 | PMID 38127487 Get It

AbstractPurposeThis paper reports the efficacy of the poly (ADP‐ribose) polymerase inhibitor olaparib alone and in combination with the antiangiogenesis agent cediranib compared with cediranib alone in patients with advanced endometrial cancer.MethodsThis was open‐label, randomized, phase 2 trial (NCT03660826). Eligible patients had recurrent endometrial cancer, received at least one (<3) prior lines of chemotherapy, and were Eastern Cooperative Oncology Group performance status 0 to 2. Patients were randomly assigned (1:1:1), stratified by histology (serous vs. other) to receive cediranib alone (reference arm), olaparib, or olaparib and cediranib for 28‐day cycles until progression or unacceptable toxicity. The primary end point was progression‐free survival in the intention‐to‐treat population. Homologous repair deficiency was explored using the BROCA‐GO sequencing panel.ResultsA total of 120 patients were enrolled and all were included in the intention‐to‐treat analysis. Median age was 66 (range, 41–86) years and 47 (39.2%) had serous histology. Median progression‐free survival for cediranib was 3.8 months compared with 2.0 months for olaparib (hazard ratio, 1.45 [95% CI, 0.91‐2.3] p = .935) and 5.5 months for olaparib/cediranib (hazard ratio, 0.7 [95% CI, 0.43–1.14] p = .064). Four patients receiving the combination had a durable response lasting more than 20 months. The most common grade 3/4 toxicities were hypertension in the cediranib (36%) and olaparib/cediranib (33%) arms, fatigue (20.5% olaparib/cediranib), and diarrhea (17.9% cediranib). The BROCA‐GO panel results were not associated with response.ConclusionThe combination of cediranib and olaparib demonstrated modest clinical efficacy; however, the primary end point of the study was not met. The combination was safe without unexpected toxicity.
NCCN Guidelines® Insights: Cervical Cancer, Version 1.2024
Abu‐Rustum, Nadeem R. , Yashar, Catheryn M. , Arend, Rebecca C. , Barber, Emma L. , Bradley, Kristin , Brooks, Rebecca , Campos, Susana M. , Chino, Junzo , Chon, Hye Sook, Damast, Shari , Fisher, Christine M. , Frederick, Peter J., Gaffney, David K. , Gaillard, Stéphanie , Giuntoli, Robert , Glaser, Scott , Holmes, Jordan A. , Howitt, Brooke E. , Mantia-Smaldone, Gina , Mariani, Andrea , Nagel, Christa , Nekhlyudov, Larissa , Podoll, Mirna, Rodabaugh, Kerry J. , Salani, Ritu , Schorge, John O., Siedel, Jean , Sisodia, Rachel , Soliman, Pamela T. , Ueda, Stefanie , Urban, Renata R. , Wyse, Emily , McMillian, Nicole R., Aggarwal, Shaili, Espinosa, Sara, Gaillard, Stéphanie , Crispens, Marta Ann , Lea, Jayanthi Sivasothy , Mutch, David G.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | December 11, 2023 | Volume: 21 | Issue: 12 | Pages: 1224-1233

10.6004/jnccn.2023.0062 | PMID 38081139 Get It

The NCCN Guidelines for Cervical Cancer provide recommendations for all aspects of management for cervical cancer, including the diagnostic workup, staging, pathology, and treatment. The guidelines also include details on histopathologic classification of cervical cancer regarding diagnostic features, molecular profiles, and clinical outcomes. The treatment landscape of advanced cervical cancer is evolving constantly. These NCCN Guidelines Insights provide a summary of recent updates regarding the systemic therapy recommendations for recurrent or metastatic disease.
Cannabidiol (CBD) Treatment Effect and Adverse Events (AEs) by Time in Patients with Lennox-Gastaut Syndrome (LGS): Pooled Results from 2 Trials (S19.006)
Privitera, Michael , Bhathal, Hari, Wong, Matthew H. , Cross, J. Helen , Sommerville, Kenneth W. , Cross, Helen J , Wirrell, Elaine , Wong, Matthew H.

Mayo Clinic

Neurology | December 7, 2023 | Volume: 90 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.90.15_supplement.s19.006 Get It

Neurosarcoidosis in a public safety net hospital: a study of 82 cases (P2.389)
Dorman, James, Warrior, Lakshmi, Pandya, Vishal , Sun, Ying , Ninan, Jacob , Trick, William E. , Zhang, Helen

Mayo Clinic

Neurology | December 7, 2023 | Volume: 88 | Issue: 16_supplement | Pages: No page available

10.1212/wnl.88.16_supplement.p2.389 Get It

HJKC3-0006: Outcome of Patients with CML Treated on Second Line or Later Therapy in Routine Clinical Practice
Thompson, James E. , Gao, Yan , Visotcky, Alexis, Mauro, Michael J. , Giever, Emily, Baim, Arielle , Akinola, Idayat , Cortes, Jörge E. , Shah, Neil P. , Pinilla‐Ibarz, Javier , Yang, Jay , Ritchie, Ellen K. , Rein, Lindsay , Tantravahi, Srinivas K. , Deininger, Michael W. , Cortes, Jorge , Visotcky, Alexis, Flynn, Kathryn E. , Larson, Richard A. , Jamy, Omer , Hunter, Anthony M. , Kota, Vamsi , Druker, Brian J , Smith, B. Douglas , Badar, Talha , Atallah, Ehab

Mayo Clinic

Blood | December 2, 2023 | Volume: 142 | Issue: Supplement 1 | Pages: 7420-7420

10.1182/blood-2023-179963 Get It

Background: First-line therapies for chronic-phase (CP) CML include the tyrosine kinase inhibitors(TKIs) dasatinib, nilotinib, bosutinib or imatinib, while ponatinib and asciminib are indicated only in later lines. There are typically high response rates to first-line therapy in CP-CML, with responses to second- and third-line therapy lower and highly dependent on the specific TKI. Our goal in this study is to evaluate the role of ponatinib in the treatment of patients with CML using data from routine clinical practice. Study design and methods: Data will come from the H. Jean Khoury Cure CML Consortium (HJKC3) CML registry, a North American multi-site research database. Participating sites include the HJKC3 members (curecml.org). Patient inclusion criteria include a diagnosis CML in chronic phase, receiving second line therapy after initial therapy with a second generation TKI (dasatinib, nilotinib, or bosutinib) or receiving third or later line TKI therapy for CML. Participating patients provide consent to collect their data both retrospectively and prospectively for 1 year. Clinical data, including toxicities and complications of TKI therapy, are abstracted from the electronic health record. Participating patients are invited to complete a questionnaire to assess health-related quality of life. Data are managed using REDCap, a secure web application. Study Objectives: The primary objective is to compare the outcome of patients treated with ponatinib vs. other TKIs as second or later line therapy. Secondary objectives are to evaluate patient-reported outcomes (PRO) for CML treated with second or later line therapy and to determine if there are any patient or disease characteristics that can predict outcomes. Statistical plan for clinical outcomes: Descriptive statistics will be used to compare baseline demographic characteristics. Categorical variables will be compared using the Chi-square test. Continuous variables will be compared using ANOVA. Overall survival will be calculated from the time of diagnosis to death from any cause and patients will be censored if they were alive at the last follow-up. Survival probabilities will be computed using the Kaplan-Meier method and compared with the log-ranktest. Cox regression analyses will be used to determine significant factors that influence survival, and hazard ratios with 95% confidence intervals will be presented. Event free survival (EFS) and transformation free survival (TFS) will be calculated for patients. For EFS, loss of complete hematologic remission, loss of major cytogenetic response, progression to accelerated or blast phase, or death from any cause at any time will be considered an event. For TFS, transformation to accelerated or blast phase while on therapy or death on study will be considered an event. Statistical plan for PRO: Different PRO domains will be analyzed separately (for example, depression separate from fatigue, etc.). Descriptive statistics for each PRO measure will be reported and compared to previously published studies. Differences by treatment type will be evaluated.